Related Experiment Video

Updated: May 22, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)

Published on: February 9, 2011

Community acquired methicillin resistant Staphylococcus aureus pneumonia: an update for the emergency and intensive

I Karampela1, G Poulakou, G Dimopoulos

  • 1Department of Critical Care Medicine, University Hospital Attikon, Medical School University of Athens, Athens, Greece.

Minerva Anestesiologica
|April 26, 2012
PubMed

Insights

Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) causes severe pneumonia, particularly in young individuals. Early suspicion and aggressive intravenous antibiotic treatment are crucial for better outcomes in these rapidly progressive infections.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pulmonology

Background:

  • Community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) emerged as a significant pathogen a decade ago.
  • CA-MRSA is associated with severe, rapidly progressive, and often fatal diseases, including necrotizing pneumonia.
  • The epidemiology and optimal management of CA-MRSA pneumonia remain incompletely understood and geographically variable.

Purpose of the Study:

  • To review the current understanding of CA-MRSA pneumonia.
  • To highlight the clinical presentation, risk factors, and treatment strategies for CA-MRSA pneumonia.

Main Methods:

  • Literature review and synthesis of existing data on CA-MRSA pneumonia.
  • Analysis of clinical manifestations, microbiological characteristics, and therapeutic approaches.

Main Results:

  • CA-MRSA strains possess unique genetic traits, including methicillin resistance and Panton-Valentine leukocidin (PVL) production, contributing to enhanced virulence.
  • Clinical presentation often includes rapid progression with cavitary consolidation, bilateral infiltrates, pleural effusion, and hemoptysis, especially in young, healthy individuals.
  • Treatment necessitates prompt hospitalization and aggressive intravenous antibiotic therapy, often mirroring strategies for hospital-acquired MRSA (HA-MRSA) infections.

Conclusions:

  • Early clinical suspicion and prompt, aggressive management are vital for improving outcomes in CA-MRSA pneumonia.
  • Further research into novel anti-MRSA agents and combination therapies is warranted for severe CA-MRSA infections.

More Related Videos

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: